Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-LNCab002
- Development stage
- Phase 1
- Lead developer
- Affiliated Hospital of Jiangnan University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**89Zr-LNCab002** is a radiolabeled monoclonal antibody designed for positron emission tomography (PET) imaging of **HER2-positive malignancies**. It consists of a humanized monoclonal antibody targeting the **HER2** (human epidermal growth factor receptor 2) protein, conjugated with the radioisotope **Zirconium-89 (89Zr)**. This agent is in early clinical development for non-invasive diagnosis, disease staging, and evaluation of HER2 expression in cancers such as **breast cancer, gastric cancer, and urothelial carcinoma**. The radiolabeled antibody enables highly specific imaging of HER2-expressing tumors and metastases, supporting both initial detection and therapeutic monitoring. The drug has been developed primarily by the Affiliated Hospital of Jiangnan University for diagnostic use in oncology[1][3].
- Brand names
- 89Zr-LNCab002
- Other names
- 89Zr-LNCab002
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on 89Zr-LNCab002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-LNCab002.